TABLE 3.

Summary clinical agreements for 0–55 h for each site

Data analysis set	Overall agreement [% (n; 95% CI)]	Positive agreement with (95% CI)	Negative agreement with (95% CI)
All study results	96.9 (1,792/1,850; 96.0–97.6)	95.9 (397/414; 93.5–97.6)	97.1 (1,395/1,436; 96.1–97.9)
Site 1 results	94.8 (363/383; 92.1–96.8)	98.8 (335/339; 97.0–99.7)	63.6 (28/44; 47.8–77.6)
Site 2 results	88.7 (102/115; 81.4–93.8)	84.9 (45/53; 72.4–93.3)	91.9 (57/62; 82.2–97.3)
Site 3 results	98.0 (248/253; 95.4–99.4)	100 (6/6; 54.1–100.0)	98.0 (242/247; 95.3–99.3)
Site 4 results	98.2 (1,079/1,099; 97.2–98.9)	68.8 (11/16; 41.3–89.0	98.6 (1,068/1,083; 97.7–99.2)
0–8 h (all sites)	96.5 (574/595; 94.7–97.8)	98.0 (145/148; 94.2–99.6)	96.0 (429/447; 93.7–97.6)
18–32 h (all sites)	96.4 (556/577; 94.5–97.7)	94.9 (129/136; 89.7–97.9)	96.8 (427/441; 94.7–98.3)
39–46 h (all sites)	98.0 (193/197; 94.9–99.4)	50.0 (2/4; 6.8–93.2)	99.0 (191/193; 96.3–99.9)
48–55 h (all sites)	97.5 (469/481; 95.7–98.7)	96.0 (121/126; 91.0–98.7)	98.0 (348/355; 96.0–99.2)